Bristol Myers Squibb (CELG-RI) Return on Equity (2009 - 2026)

Bristol Myers Squibb has disclosed Return on Equity across 17 years of filings, most recently posting 0.0% for Q1 2026.

• In Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, up 2.0% from the prior year.
• Return on Equity slipped to 0.0% in Q1 2026, from 0.0% in the prior quarter.
• Over the last five years, Return on Equity for CELG-RI reached as high as 0.29% in Q2 2025 and fell as low as 0.25% in Q3 2024.
• The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.01%.
• Annual changes were most pronounced in 2024 — Return on Equity fell 23 bps — and 2025, when it rose 29 bps.
• A 5-year view of Return on Equity shows it stood at 0.06% in 2022, then surged by 110 bps to 0.01% in 2023, then sank by 295 bps to 0.01% in 2024, then surged by 132 bps to 0.0% in 2025, then decreased by 1 bps to 0.0% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.0%, 0.0%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.